bluebird bio’s gene therapy platform holds the promise of delivering a one-time treatment for a wide variety of diseases. The company’s initial focus is on genetic diseases caused by a known mutation in a single gene. Through the application of gene therapy, bluebird is developing product candidates designed to insert a functional gene into a patient, potentially correcting their underlying disease. In addition to genetic diseases, bluebird and its partners are also utilizing this technology to develop product candidates intended to treat various cancers, by targeting a patient’s own immune system to seek out and kill cancer cells in the body, offering a new approach to cancer treatment.
“bluebird bio is seeking to bring transformative gene therapies to
The head of the New Champions at the
bluebird bio and the 2014 Technology Pioneers will be honored at the
Forum’s Annual Meeting of the New Champions 2013 in
About bluebird bio, Inc.
bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases. bluebird bio has two clinical-stage programs in development. The most advanced product candidate, Lenti-D, recently initiated a phase 2/3 study for the treatment of childhood cerebral adrenoleukodystrophy (CCALD), a rare, hereditary neurological disorder affecting young boys. The next most advanced product candidate, LentiGlobin, is currently in a phase 1/2 study in
bluebird bio also has an early-stage chimeric antigen receptor-modified
T cell (CAR-T) program for oncology in partnership with
bluebird bio has operations in
This release contains “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, including
statements regarding the clinical potential of bluebird bio’s gene
therapy platform and product candidates and the advancement and stage of
its clinical trials. Any forward-looking statements in this press
release are based on management's current expectations of future events
and are subject to a number of risks and uncertainties that could cause
actual results to differ materially and adversely from those set forth
in or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to, risks associated with
gene therapy generally, which is a novel technology and not yet approved
as a therapeutic modality in
Source: bluebird bio, Inc.
bluebird bio, Inc
Richard E. T. Smith, Ph.D., 617-588-3321
Pure Communications, Inc.
Dan Budwick, 973-271-6085